A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Jacqueline M KravekaElizabeth C LewisGenevieve BergendahlWilliam FergusonJavier OesterheldElizabeth KimAbhinav B NagulapallyKarl J DykemaValerie I BrownWilliam D RobertsDeanna MitchellDon EslinDerek HansonMichael S IsakoffRandal K WadaVirginia L HarrodJawhar RawwasGina HannaWilliam P D HendricksSara A ByronMatija SnuderlJonathan SerranoJeffrey M TrentGiselle L Saulnier Sholler

Published in: Cancer reports (Hoboken, N.J.) (2022)

This study demonstrates the safety and feasibility of adding targeted agents to standard induction therapy and adding DFMO to immunotherapy for HRNB. This treatment regimen has been expanded to a Phase II trial to evaluate efficacy.

Keyphrases

randomized controlled trial
clinical trial
stem cells
open label
cancer therapy
mesenchymal stem cells
copy number
replacement therapy
cell therapy